To assess the role of CCL2/MCP-1 in opiate drug abuse and HIV-1 comorbidity, the effects of systemic morphine and intrastriatal HIV-1 Tat on macrophage/microglial and astroglial activation were assessed in wild type and CCR2 null mice. Tat and/or morphine additively increased the proportion of CCL2 immunoreactive astroglia. The effects of morphine were prevented by naltrexone. Glial activation was significantly reduced in CCR2(−/−) versus wild-type mice following Tat or morphine plus Tat exposure. Thus, CCR2 contributes to local glial activation caused by Tat alone or in the presence of opiates, implicating CCR2 signaling in HIV-1 neuropathogenesis in drug abusers and non-abusers.
Introduction
Opiates (substances derived from the opium poppy, such as heroin, morphine, or analogues such as oxycodone) are popular drugs of abuse that exacerbate the pathogenesis of human immunodeficiency type 1 (HIV-1) infection through preferential actions at endogenous μ-opioid receptors (MOR) (Gurwell et al., 2001; Hauser et al., 2005 Hauser et al., , 2006 . There is considerable evidence that opiate drugs can exacerbate HIV-1 encephalitis (HIVE) by modulating the expression and function of neuroimmune chemokines and their receptors (Rogers and Peterson, 2003) . Importantly, the effects of opiates are not restricted to a particular cell type, and opiates per se directly affect the expression of chemokine ligands and receptors in neural (neurons, microglia, and astroglia) and non-neural cells (lymphocytes and monocytes/macrophages) (Hauser et al., 2005) .
Chemokines mediate multiple inflammatory disorders in the CNS, including multiple sclerosis (Mahad and Ransohoff, 2003) and HIVE (Nath, 1999; Kaul et al., 2001) . CC chemokine ligand 2 [CCL2, also known as monocyte chemoattractant protein-1 (MCP-1)], in particular, is a cofactor in HIV-1 pathogenesis and appears to initiate and sustain the neuroinflammatory process. CCL2 attracts and activates mononuclear phagocytes, as well as several other leukocyte types, to sites of CNS injury (McManus et al., 2000) . CCL2 levels correlate with neurocognitive deficits accompanying HIV-1 or simian immunodeficiency virus infection (Sevigny et al., 2004; Mankowski et al., 2004;  
